Background
==========

More than 50% of worldwide esophageal squamous cell carcinoma (ESCC) patients are located in China [@B1]. There is no consensus about the combined therapeutic strategy for ESCC in China due to lack of randomized controlled trials (RCT). Although the multidisciplinary therapeutic strategies have been explored for many years in both western countries [@B2]-[@B7] and Japan [@B8], the treatment is quite different from region to region based on the results of local RCTs.

The North American intergroup trial for ESCC (Radiation Therapy Oncology Group, RTOG Trial 8911 or USA Intergroup 113) [@B2], [@B3] suggested that there was no survival benefit from NAC for ESCC, whereas the Japan Clinical Oncology Group trial (JCOG9907) [@B8] showed promising results for the same procedure. The survival benefit of neoadjuvant chemotherapy (NAC) for ESCC remains controversial worldwide [@B9], [@B10]. Due to contradictory evidence outside China and the lack of RCT in China, we collected data from published articles and found the quality control of surgical procedures in the RCTs was poor [@B11]. At that time, lymph node sampling and transthoracic esophagectomy, transhiatal esophagectomy were acceptable in some trials. Surgery was the only local control method that existed in the NAC strategy. Different surgical procedures and ranges of lymphadenectomies may mask the benefits of chemotherapy and significantly affect the survival rate.

In light of past RCTs [@B2]-[@B5], [@B8], we have designed a retrospective analysis in our institute. The main concern of this study was to declare the survival benefit of NAC-platinum plus paclitaxel (TP) over the primary surgery based on quality controlled and standardized surgical procedure. Minimally invasive esophagectomy with total two-field lymphadenectomy was the only used surgical procedure.

Methods
=======

Inclusion criteria
------------------

The Ethics Review Committee of Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou University approved this study officially. The approval number is 2016ct081. Patients\' personal data were obtained. The consecutive patients were retrospectively evaluated between 06/2011 and 12/2014. The inclusion criteria were as follows: i) Thoracic ESCC; ii) Clinical staging T2-4aN0-2; iii) MIE with total two-field lymphadenectomy; iv) With follow up, without clinical missing data. The TNM Classification of Malignant Tumors 7th edition was adopted for the clinicopathological profiles [@B12].

Neoadjuvant Chemotherapy
------------------------

NAC comprised 2 cycles. Cisplatin or nedaplatin plus paclitaxel were repeated once every 3 weeks. A dose of 175 mg/m2 paclitaxel was given by intravenous drip infusion on days 1 and 8. Cisplatin or nedaplatin was administered at a dose of 75 mg/m2 by continuous infusion on days 2-4.

Surgical procedure
------------------

All patients received a right thoracolaparoscopic esophagectomy and at least 2-field lymph node dissections. Cervical lymphadenectomy was performed when suspicious lymph node metastasis was reported on a color ultrasound. First, the patient was placed in a left semi-prone-position. The thoracic esophagus was mobilized and the lymph nodes were dissected. The regional lymph nodes included the mediastinal lymph nodes (left recurrent laryngeal never, right recurrent laryngeal nerve, paraesophageal, paratracheal, subcarinal, supradiaphragmatic and posterior mediastinal lymph nodes). Then the position was modified to a supine position. A 2-3 cm left cervical incision was made. Muscle sparing methods and blunt dissection were used to expose the cervical esophagus. In the abdominal part, laparoscope was used for gastric mobilization. A 3-cm gastric tube was made with linear staplers (TLC, Ethicon, USA) and perigastric lymph nodes (celiac, left gastric artery, common hepatic artery and splenic artery lymph nodes were dissected. Finally, the gastric conduit was delivered to the neck to be sewn with the distal esophagus by using a hand-sewn 3 layered anastomosis (Li\'s anastomosis) [@B13]. Figure [1](#F1){ref-type="fig"} showed the standard extent of lymph nodes dissection.

Clinical and Pathological Tumor Effects
---------------------------------------

Preoperational investigations included esophagography, esophageal endoscopic ultrasound, esophagoscopy, contrast-enhanced thoracic CT scan, abdominal ultrasound, brain MRI, cervical color ultrasound, and Emission Computed Tomography (ECT). If a patient accepted, positron emission tomography-CT (PET/CT) would be adopted instead of chest CT, abdominal ultrasound, cervical color ultrasound and ECT. No patients have repeated PET scan and endoscopy after induction. The Response Evaluation Criteria in the Solid Tumors [@B14] were used to evaluate the clinical tumor responses. Radiographic criteria for positive lymph nodes was that the shortest diameter of lymph nodes \> 1 cm and the ratio of long axis \> 0.65, The pathological complete response (pCR) was defined as no evident viable cancer cells [@B15]. Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 [@B16] was adopted to assess the adverse events of NAC.

Follow-Up
---------

All patients were followed at outpatient clinics or contacted by a research nurse by phone. Over the first 3 years, the patients received clinical and radiological evaluation every 3 months. For the next 2 years, the patients were examined every 6 months. After 5 years, the patients were followed annually until death. The surveillance studies after surgery included chest CT scans, abdominal and cervical ultrasound. PET/CT, abdominal CT scan, endoscopy, brain MRI and ECT were performed depending on the patient\'s status.

Statistical Analysis
--------------------

The SPSS 23.0 software for Windows (SPSS, Chicago, IL, USA) was used to perform the statistical analysis. The propensity score (PS) matched analysis was used to reduce the bias. PS was calculated to fit with variables, including age, sex, length of tumor, location of tumor, clinical T stage, clinical N stage and clinical TNM stage. The characteristics and pre-therapy data between the groups were compared using Student\'s *t*-test for all quantitative data and both a chi-square test and a Mann-Whitney U test for qualitative data. Categorical variables were compared by Fisher\'s exact test. The Kaplan-Meier method was adopted to analyze overall survival (OS) with a log-rank test. We reported survival rates and Hazard ratios with 95% confidence intervals (CIs). The OS was defined as the time from the operation in the surgery group and the first date of NAC to the death or most recent follow-up. A two-sided P value of 0.05 was defined as statistically significant.

Results
=======

Patient Characteristics
-----------------------

Between 06/2011 and 12/2014, there were 279 consecutive patients who meet the criterion; 83 received NAC and 196 primary surgery. After PS matched analysis, there were 76 matched primary surgery patients (Figure [3](#F3){ref-type="fig"}). The characteristics of the 159 patients after PS matching were summarized in Table [1](#T1){ref-type="table"}. The primary data was comparable. The NAC group had much earlier pathological stage (P\<0.001).

Clinical Effect of Neoadjuvant Chemotherapy
-------------------------------------------

CR to NAC were observed in 16 (19.3%) patients, partial responses (PR) in 48 (57.8%) patients, SD in 17 (20.5%), and progressive disease (PD) in 2 (2.4%). Therefore, the overall clinical response rate was 77.1%. During the same period, there were 6 excluded NAC patients. One patient after NAC (clinical effect, stable disease, SD) underwent R1 resection because of the invasion of aorta. Five patients didn\'t received surgery after NAC; three got progressive disease (PD) clinically and underwent definitive chemoradiotherapy. Two got clinical complete response (CR) after NAC, refused to do surgery and accepted definitive chemoradiotherapy.

Toxicity of Neoadjuvant Chemotherapy
------------------------------------

Most of the patients received 2 cycles of NAC (86.7%). Paclitaxel + NDP were the most adopted chemotherapy regimen (55.4%). Table [2](#T2){ref-type="table"} showed the toxicity of NAC. One (1.2%) patient had grade 4 leukopenia, 8 (9.6%) had grade 3 leukopenia, and 33 (39.8%) had grade 1 leukopenia. None of the patients had grade 4; hepatorenal and gastrointestinal toxicity. Only 3 patients adjusted the dose because of side effects.

Surgical Outcomes and Pathological Effects
------------------------------------------

The surgical data were shown in Table [3](#T3){ref-type="table"}. There was no significantly difference between the groups. Table [4](#T4){ref-type="table"} showed the clinical response to NAC. Based on RECIST 1.0 [@B14], 19.3% of patients had CR, 57.8% had PR, 20.5% had SD and 2.4% had PD. The pathological response rate (pCR) was 20.5%.

Survival
--------

The median follow-up for all of the patients was 36 months (ranging from 6 to 68). Figure [2](#F2){ref-type="fig"} described the OS of patients between the two groups with the Kaplan-Meier method, and a log-rank test was used. The five-year estimated OS rates for the NAC group and surgery group were 71.7% and 45.3%, respectively. The mean survival time for the NAC group was 54.359 months (log-rank, 95% CI, 50.417 to 58.301). The mean survival period was 49.353 months for the primary surgery group (log-rank, 95% CI, 43.770 to 54.936). The estimate median survival time for surgery group was 51 months. However, the median survival time for the NAC group has not yet been reached. Seventeen pCR patients were all alive. Only one of them had recurrence in lung in 56 months after the first day of NAC.

Discussion
==========

Our study demonstrated that NAC with TP followed by MIE with total two-field lymphadenectomy improved OS comparing with primary surgery. There are 2 possible reasons for the better NAC results. First, NAC-TP got a high clinical (77.1%) and pathological (20.5%) response rate. Second, the standarlized two-field lymphadenectomy MIE. In a study assessing the outcome of NACR followed by surgery, en bloc esophagectomy was compared with a transhiatal esophagectomy. The more radical surgery was an independently better survival factor, regardless of the response to NACR [@B17]. Another study on NACR for patients with ESCC showed that the degree of lymph node dissection significantly influenced the OS [@B18]. Compared with NACR, NAC didn\'t have the effect for local control. The quality of the operation was more important in NAC than NACR for EC [@B19]. In the 3 large multicenter clinical trials on NAC, too little attention was given to standardize the surgical procedure [@B19]. All the cases included in our study represent the results of a single surgeon\'s experience. That was easy to standardize surgical procedure.

The side effects toxicity of TP-NAC was tolerable. Hepatorenal disorder (grade 1) was the most common side effect (44.6%) in the present study. Only 1 (1.2%) patient had Grade 4 bone marrow depression. The vomiting and stomatitis were another common side effect, occurring in 4.8% of the patients (4 cases). The adverse effects of weekly paclitaxel and a 21-day cycle of cisplatin were mild. Due to the overall mild non-hematological and hematological toxicities, the weekly TP regimen was tolerable for many patients.

Esophageal surgery is usually associated with a high postoperative morbidity and mortality. However, our data shown the postoperative mortality was zero. After NAC, the incidence of postoperative morbidity and mortality has not increased among patients compared to patients treated by primary surgery. There was no significant difference in complication rate between two groups. MIE after NAC was safe.

The rates of pCR in patients treated with NAC ranged from 2% to 17% in previous reports of this combined strategy [@B11], whereas we achieved a pCR rate of 20.5% for primary tumors and the lymph nodes, which was relatively high. In previously reports, NACR could achieve a 20%-40% pCRT rate. The high pCR rate might be explained by the fact that the TP regime was adopted in this study, whereas in the past CF was mostly adopted. More and more studies have reported that paclitaxel cell toxicity is effective for treating squamous cell carcinoma (SCC) [@B20]. Based on the retrospective data and clinical experience, weekly paclitaxel was tolerable, might have been related to the high pCR rate. As a retrospective study, there must be some selection bias, which may also have contributed to the high pCR rate. That was also the reason why we wanted to start a RCT.

The ESCC mostly occurs in less-developed regions of the world. More than 50% of the ESCC cases were located in China (53%, 210 000 cases) [@B1]. Henan province carried the highest burden of ESCC in China [@B21]. Based on huge patient number, in light of past trials and the results of our studies, we designed the multicenter RCT in China [@B22]. Compared with past trials, we emphasized standard surgical procedures and a standard range of lymphadenectomy. The recruitment of 528 cases will be done within 2.5 years ClinicalTrials.gov Identifier: NCT02395705. Hopefully, it will provide a conclusion for the using of NAC with total two-field lymphadenectomy for ESCC.

Conclusions
===========

NAC with TP followed by MIE with total two-field lymphadenectomy is better than primary surgery in terms of OS without additional serious adverse events. This combined therapy might be a highly recommended treatment modality for patients with stage II/III ESCC.
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![Kaplan-Meier survival analysis of ESCC patients (n = 159). The survival rate of patients in the NAC group was higher than patients in the surgery alone group (log-rank test, P = 0.049).](jcav10p1097g002){#F2}

![Between 06/2011 and 12/2014, there were 279 consecutive patients who meet the criterion; 83 received NAC and 196 primary surgery. After PS matched analysis, there were 76 matched primary surgery patients. Finally, there were 159 patients included in this study. ESCC, esophageal squamous cell carcinoma; NAC, neoadjuvant chemotherapy; PS, propensity score.](jcav10p1097g003){#F3}

###### 

Characteristics and pre-therapy data of patients with ESCC after and before the propensity score matching

  Characteristics                                                                                                      Number (%)                 Different strategy             
  -------------------------------------------------------------------------------------------------------------------- ------------ ------------- -------------------- --------- ----------------
  **Characteristics and pre-therapy data of patients with ESCC after the propensity score matching in 159 patients**                                                             
  **Age Y (Mean±SD)**                                                                                                               60.47±0.973   60.6±0.824           2.719     0.101
  Range                                                                                                                             40-74         42-81                          
  **Gender N (%)**                                                                                                                                                     0.003     0.955
  Male                                                                                                                 130(81.8)    62(81.6)      68(81.9)                       
  Female                                                                                                               29(18.2)     14(18.4)      15(18.1)                       
  **Location N (%)**                                                                                                                                                   2.476     0.290
  Upper thoracic                                                                                                       35(22.0)     15(19.7)      20(24.1)                       
  Middle thoracic                                                                                                      71(44.7)     31(40.8)      40(48.2)                       
  Lower thoracic                                                                                                       53(33.3)     30(39.5)      23(27.7)                       
  **Clinical TNM staging 7^th^ ed N (%)**                                                                                                                              0.297     0.586
  cStageⅡ                                                                                                              78(49.1)     39(51.3)      39(47.0)                       
  cStageⅢ                                                                                                              81(50.9)     37(48.7)      44(53.0)                       
  **Adjuvant therapy**                                                                                                                                                 \<0.001   0.982
  Yes                                                                                                                  94(59.1)     45(59.2)      49(59.0)                       
  No                                                                                                                   65(40.9)     31(40.8)      34(41.0)                       
  **Adjuvant radiation**                                                                                                                                               0.202     0.653
  Yes                                                                                                                  19(11.9)     10(13.2)      9(10.8)                        
  No                                                                                                                   140(88.1)    66(86.8)      74(89.2)                       
  **Pathological TNM staging 7^th^ ed N(%)**                                                                                                                                     \<0.001**^a^**
  pCR                                                                                                                  17(10.7)     NA            17(20.5)                       
  I                                                                                                                    14 (8.8)     6(7.9)        8(9.6)                         
  II                                                                                                                   74 (46.5)    42(55.3)      32(38.6)                       
  III                                                                                                                  53 (33.3)    27(35.5)      26(31.3)                       
  IV                                                                                                                   1 (0.6)      1(1.3)        0                              

ESCC, esophagus squamous cell carcinoma; Y, years; N, number; c, clinical; TNM, pathological tumor/node/metastasis; NAC, neo adjuvant chemotherapy; S, surgery; **^a^** Fisher exact test Statistically significant (*p* \< 0.05); pCR, pathological complete response; **^b^** Statistically significant (*p* \< 0.05)

###### 

Side effects of NAC

  --------------------------------------------------------------------------------------
  Toxicity                        Grade 0\   Grade 1\   Grade 2\   Grade 3\   Grade 4\
                                  N (%)      N (%)      N (%)      N (%)      N (%)
  ------------------------------- ---------- ---------- ---------- ---------- ----------
  **Leukopenia**                  39(47)     33(39.8)   8(9.6)     2(2.4)     1(1.2)

  **Gastrointestinal symptoms**   37(44.6)   31(37.3)   11(13.3)   4(4.8)     0

  **Hepatorenal disorder**        43(51.8)   37(44.6)   3(3.6)     0          0
  --------------------------------------------------------------------------------------

^a^, Common Terminology Criteria for Adverse Events Version 3.0; N, number.

###### 

Operation data for both groups

  Variable                                                  NAC+S (n=83)   S (n=76)        *p* Value
  --------------------------------------------------------- -------------- --------------- -----------
  **Operation time(minutes), Mean±SD**                      227.94±39.57   239.74±47.293   0.089
  **EBL (ml), median (range)**                              100 (50-400)   70 (30-400)     0.093
  **Total nodes collected, median (range)**                 16 (15-69)     16 (15-42)      0.608
  **Pathologically positive lymph nodes, median (range)**   0(0-28)        0(0-9)          0.582
  **Postoperative days, median (range)**                    9 (5-30)       8 (5-32)        0.052
  **Hospital mortality, (%)**                               0              0               NA
  **Complication, N (%)**                                   20(24.1)       19(25.0)        0.895
  Pneumonia                                                 11(13.3)       9(11.8)         0.789
  Arrhythmia                                                7(8.4)         6(7.9)          0.901
  Anastomotic leakage                                       2(2.4)         1(1.3)          \>0.99
  Incision infection                                        4(4.8)         2(2.6)          0.759
  Recurrent laryngeal nerve injury                          16(19.3)       13(17.1)        0.723
  Chylothorax                                               0              1(1.3)          0.478

NAC, neoadjuvant chemotherapy; S, surgery; EBL, estimated blood loss; N, number; NA, not applicable; ^a^ Statistically significant (*p* \< 0.05).

###### 

Response evaluation of the patients with ESCC to NAC

  Characteristics           Variable      Absolute value (%)
  ------------------------- ---------- -- --------------------
  **Radiologic response**   CR            16(19.3)
                            PR            48(57.8)
                            SD            17(20.5)
                            PD            2(2.4)
  **Pathologic response**   CR            17(20.5)
                            other         66(79.5)
  **Down staging**          Yes           33(39.8)
                            No            50(60.2)

ESCC, esophagus squamous cell carcinoma; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
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